Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01350947 · ClinicalTrials.gov registry record · Phase 2
A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
A Phase 2 study of Chronic Myelomonocytic Leukemia, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 3
- Study locations
NCT01350947 is a Phase 2 study of Chronic Myelomonocytic Leukemia that has completed, run by University of Utah. The registered enrollment target is 11 participants, below the 89-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01350947, a Phase 2 study of Chronic Myelomonocytic Leukemia, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of this study is: Response to treatment will be evaluated according to the revised International Working Group (IWG) categories natural history, hematologic improvement and cytogenetic response1;2. The primary objective is: To determine the rate of complete hematologic response and hematologic improvement (according to IWG 2006 criteria) in CMML patients treated with 5-azacitidine.
Conditions Studied
Interventions
- DRUG 5-Azacitidine
Study Locations (3)
New York
- Roswell Park Cancer Institute - Buffalo
Oregon
- Oregon Health and Science University - Portland
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01350947
The ClinicalTrials.gov registry entry for NCT01350947 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (88% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which 5-Azacitidine is the first listed.
NCT01350947 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Oregon, Utah.
Frequently Asked Questions
What is clinical trial NCT01350947 about?
NCT01350947 is a clinical study titled "A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia". The primary objective of this study is: Response to treatment will be evaluated according to the revised International Working Group (IWG) categories natural history, hematologic improvement and cytogenetic response1;2. The primary objective is: To determine the rate of complete hematologic respon...
What is the current status of trial NCT01350947?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2011-04. Estimated completion is 2014-09.
What conditions does trial NCT01350947 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia.
What interventions are being tested in trial NCT01350947?
The interventions under investigation include: 5-Azacitidine (DRUG).
Who is sponsoring clinical trial NCT01350947?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01350947 being conducted?
This trial has 3 study locations across New York, Oregon, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RECRUITING · Phase 2
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.